Use the same quantitative assay and specimen type. No universal 1,000 IU/mL treatment threshold applies. Risk, symptoms and viral trajectory matter. Selected high-risk patients benefit from weekly surveillance for 8–12 weeks after prophylaxis.
Oral valganciclovir suits nonsevere disease with reliable absorption. Severe disease favors IV ganciclovir. Monitor DNAemia weekly. Treat for at least two weeks, until symptoms resolve and the assay-specific endpoint is reached: one result below quantification with a highly sensitive assay or two weekly results with a less sensitive assay. Secondary prophylaxis is individualized.
| Adult CrCl, mL/min | Treatment / induction | Prevention / maintenance |
|---|---|---|
| ≥60 | 900 mg twice daily | 900 mg daily |
| 40–59 | 450 mg twice daily | 450 mg daily |
| 25–39 | 450 mg daily | 450 mg every 2 days |
| 10–24 | 450 mg every 2 days | 450 mg twice weekly |
| <10 / hemodialysis | No adult tablet dose is provided by the label. Obtain specialist dosing. | |
Label-based renal table, using adult creatinine clearance rather than automatically substituting indexed eGFR. Take with food. Recalculate as kidney function changes. Monitor CBC and renal function. The label specifies 100 days for adult heart prophylaxis, while consensus guidance individualizes duration by risk.
| Drug | Boundary to remember |
|---|---|
| Letermovir | The cited US label covers selected HSCT and high-risk kidney recipients. Heart-transplant prevention is off-label. It is not a substitute treatment for active CMV. Review interactions, including cyclosporine. |
| Maribavir | For refractory post-transplant CMV, with or without resistance. Adult dose: 400 mg twice daily. Do not combine with ganciclovir/valganciclovir because of antagonism. Monitor immunosuppressant levels and virologic relapse. |
ART selection depends on prior resistance and treatment history. An interaction-friendly regimen must still be fully active against the patient’s HIV.
| Regimen feature | Transplant implication |
|---|---|
| Unboosted bictegravir or dolutegravir | Preferred foundations for most transplant candidates and recipients when otherwise appropriate. |
| Ritonavir, cobicistat or protease-inhibitor regimens | Can markedly increase calcineurin- and mTOR-inhibitor exposure. Generally avoid when an effective alternative is available. |
| Efavirenz, etravirine or nevirapine | Enzyme induction can lower immunosuppressant exposure. Generally avoid when possible. |
| TAF versus TDF | TAF is generally preferred because of lower renal and bone toxicity. Preserve adequate HBV-active therapy when HBV is present. |
| Starting or stopping an interacting drug | Both transitions can destabilize tacrolimus, cyclosporine or sirolimus exposure. Use therapeutic drug monitoring before, during and after the change. |
Source: NIH adult/adolescent ART guidance, transplant section. A generic twice-weekly tacrolimus schedule cannot replace measured exposure and specialist adjustment.
Avoid ART interruption. If swallowing or absorption is unreliable, arrange a formulation/route plan with HIV pharmacy. Check HIV RNA and CD4 trajectory, immunosuppressant concentrations, organ function, vaccination and opportunistic-infection prevention. Reassess after rejection treatment or any medication change.
For HCV-negative recipients of viremic non-liver grafts, guidance recommends pangenotypic therapy immediately before/day 0, or day 0–7 once stable. Recipient viremia need not be demonstrated first.
| Adult regimen | Guidance duration |
|---|---|
| Glecaprevir / pibrentasvir 300 / 120 mg daily | 8 weeks with prophylactic/preemptive initiation. Extend to 12 weeks if initiation is beyond the first post-transplant week. |
| Sofosbuvir / velpatasvir 400 / 100 mg daily | 12 weeks. |
Review liver dysfunction, amiodarone, acid suppression, statins and immunosuppressant interactions before selecting therapy. Protease-inhibitor regimens are unsuitable with relevant hepatic dysfunction. Verify the full current regimen guidance and labeling.
This chapter concerns the donor-viremic/recipient-uninfected non-liver pathway. Existing chronic HCV, prior DAA failure, decompensated liver disease and other complex scenarios need their own regimen assessment.
| Question | Why it matters |
|---|---|
| How low, how fast, how persistent? | Repeat CBC with differential, review ANC trajectory and other cell lines, symptoms and recent immunosuppression changes. |
| Medication exposure? | Review mycophenolate, (val)ganciclovir, TMP-SMX and other marrow-toxic drugs, with kidney function and dosing. Several causes can coexist. |
| Infection or another marrow process? | Assess CMV and other causes in context. Persistent or multilineage cytopenia may need hematology assessment rather than repeated empiric injections. |
| What protection would a hold remove? | State the CMV prevention/treatment, opportunistic-infection and rejection consequences before changing therapy. |
For CMV treatment, avoid antiviral dose reduction solely for leukopenia. Consider other marrow-toxic agents and selected G-CSF use. Severe toxicity needs a specialist alternative plan. The valganciclovir label advises avoiding use with ANC <500/µL, platelets <25,000/µL or hemoglobin <8 g/dL. Do not interpret the consensus principle as permission to ignore these warnings.
Drug-related neutropenia after solid-organ transplant is an off-label use. The cited label does not establish a universal transplant ANC trigger, fixed weight-band dose or repeat schedule. Define the indication, intended response and CBC reassessment with the transplant team.
A single-center retrospective heart-transplant cohort reported more rejection during the three months after G-CSF. Confounding limits causal inference. The finding supports individualized use and attention to graft surveillance, not automatic avoidance when neutropenia is dangerous.
Serious filgrastim risks include allergy, splenic rupture, ARDS, capillary leak, glomerulonephritis and aortitis. New left-upper-quadrant/shoulder pain, dyspnea or systemic deterioration needs assessment. Prior serious allergy to filgrastim or pegfilgrastim is a contraindication.
Read alongside Heart Transplant: infection and rejection. This is general education. Treatment and immunosuppression decisions require the treating transplant and infectious-disease teams.